PMID- 20060696
OWN - NLM
STAT- MEDLINE
DCOM- 20110617
LR  - 20131121
IS  - 1618-1433 (Electronic)
IS  - 0940-2993 (Linking)
VI  - 63
IP  - 3
DP  - 2011 Mar
TI  - Amelioration of cisplatin-induced nephrotoxicity by pravastatin in mice.
PG  - 215-9
LID - 10.1016/j.etp.2009.12.002 [doi]
AB  - This study investigated the protective effects of pravastatin against 
      cisplatin-induced nephrotoxicity and the possible mechanisms in mice. Pravastatin 
      showed significant protection as evidenced by the decrease of elevated serum 
      creatinine (CRE) and blood urea nitrogen (BUN), and improvement of 
      histopathological injury induced by cisplatin. The formation of kidney 
      malondialdehyde (MDA) with a concomitant reduction of reduced glutathione (GSH) 
      were inhibited by pravastatin, while the activities of kidney superoxide 
      dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-px) were 
      increased. The over expressions of kidney induced nitric oxide synthase (iNOS) 
      and nitrotyrosine (3-NT) were suppressed by pravastatin. Pravastatin suppressed 
      cisplatin-induced p38 mitogen-activated protein kinase (MAPK) activation in the 
      kidney of mice. These results suggest that pravastatin pre-administration can 
      prevent the nephrotoxicity induced by cisplatin. Pravastatin may exert the 
      protective effect via inhibiting oxidative and nitrosative stress.
CI  - Crown Copyright (c) 2009. Published by Elsevier GmbH. All rights reserved.
FAU - An, Yi
AU  - An Y
AD  - Department of Cardiology, The Affiliated Hospital of Qingdao University Medical 
      College, China.
FAU - Xin, Hui
AU  - Xin H
FAU - Yan, Wei
AU  - Yan W
FAU - Zhou, Xiaoxu
AU  - Zhou X
LA  - eng
PT  - Journal Article
DEP - 20100108
PL  - Germany
TA  - Exp Toxicol Pathol
JT  - Experimental and toxicologic pathology : official journal of the Gesellschaft fur 
      Toxikologische Pathologie
JID - 9208920
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antioxidants)
RN  - KXO2KT9N0G (Pravastatin)
RN  - MU72812GK0 (Creatine)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*adverse effects
MH  - Antioxidants/administration & dosage/*therapeutic use
MH  - Blood Urea Nitrogen
MH  - Blotting, Western
MH  - Cisplatin/*adverse effects
MH  - Creatine/blood
MH  - Kidney/*drug effects/enzymology/metabolism/pathology
MH  - Kidney Diseases/chemically induced/*prevention & control
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Oxidative Stress/drug effects
MH  - Pravastatin/administration & dosage/*therapeutic use
EDAT- 2010/01/12 06:00
MHDA- 2011/06/18 06:00
CRDT- 2010/01/12 06:00
PHST- 2009/08/14 00:00 [received]
PHST- 2009/12/08 00:00 [revised]
PHST- 2009/12/14 00:00 [accepted]
PHST- 2010/01/12 06:00 [entrez]
PHST- 2010/01/12 06:00 [pubmed]
PHST- 2011/06/18 06:00 [medline]
AID - S0940-2993(09)00297-8 [pii]
AID - 10.1016/j.etp.2009.12.002 [doi]
PST - ppublish
SO  - Exp Toxicol Pathol. 2011 Mar;63(3):215-9. doi: 10.1016/j.etp.2009.12.002. Epub 
      2010 Jan 8.